Breaking News Instant updates and real-time market news.

2018-04-09 07:08:12

CANF

Can-Fite BioPharma

$1.41

-0.04 (-2.76%)

07:08

04/09/18

04/09

07:08

04/09/18

07:08

Can-Fite BioPharma to present data from Phase 2 NAFDL/NASH study

Can-Fite BioPharma announced its poster presentation of the anti-inflammatory and anti-fibrogenic effects of Namodenosen in NAFLD/NASH animal model data at the International Liver Congress of the European Association for the Study of the Liver, or EASL. Can-Fite's current Phase II NAFLD/NASH study is being conducted in three Israeli sites. The company anticipates the completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.

CANFCan-Fite BioPharma

$1.41

-0.04 (-2.76%)

08/11/17

MAXM

08/11/17INITIATIONTarget $7MAXMBuy

Can-Fite BioPharma initiated with a Buy at Maxim

Maxim analyst Jason McCarthy started Can-Fite Biopharma with a Buy rating, stating that the company has multiple shots on goal in "blockbuster-sized indications" with its A3AR targeting drug piclidenoson. The analyst, who models piclidenoson commercialization in rheumatoid arthritis in 2022 followed by psoriasis in 2023, set a $7 price target on Can-Fite shares.

03/12/18

MAXM

03/12/18DOWNGRADEMAXMHold

Can-Fite BioPharma downgraded to Hold from Buy at Maxim

03/12/18

MAXM

03/12/18DOWNGRADEMAXMHold

Can-Fite BioPharma downgraded to Hold from Buy at Maxim

Maxim analyst Jason Kolbert downgraded Can-Fite BioPharma to Hold from Buy, saying the company's latest move to raise equity is no longer justifiable of a Buy rating. Kolbert notes that the equity dilution as part of the capital raise was unexpected, adding that the potential impact of raising "too little" capital may also result in more dilution down the line. The analyst also states that his concerns are hightened by limited near term catalysts as well as the expectations of operating capital burn rate of $21M this year against the company's estimated cash balance of $8M-$10M.